Gene Involved in Familial Pancreatic Cancer Identified

This article originally appeared here.
Share this content:
Gene Involved in Familial Pancreatic Cancer Identified
Gene Involved in Familial Pancreatic Cancer Identified

(HealthDay News) – Specific ataxia telangiectasia mutated (ATM) gene mutations that increase the hereditary risk of familial pancreatic ductal adenocarcinoma have been identified, according to a study published online December 29 in Cancer Discovery.

Noting that the ATM protein is a serine/threonine kinase known to be involved in the repair of double-strand DNA breaks, Nicholas J. Roberts, MD, of the Johns Hopkins Kimmel Cancer Center in Baltimore, and colleagues sought to identify the causative genes to explain a familial cluster of pancreatic cancer. Whole-genome sequences from 16 individuals from six families and whole-exome sequences from an additional 22 individuals from 10 families with familial pancreatic cancer were used to identify those with deleterious mutations. Each family included at least three members with pancreatic ductal adenocarcinoma. Known predisposition genes were eliminated, as no mutations in these genes were observed. The coding region of the ATM gene was then sequenced for an additional 166 familial pancreatic cancer probands and 190 spouse controls.

The researchers found that, overall, four of 166 familial pancreatic cancer probands (2.4 percent) carried deleterious ATM mutations. Taking into account only those families with three or more cases, four of 87 probands (4.6 percent) carried a deleterious, functional mutation in the ATM gene. Under natural conditions, these mutations are associated with a recessive disease phenotype.

"The identification of deleterious ATM mutations in probands has substantial implications for risk assessment and surveillance in other family members. Moreover, because ATM is a key participant in DNA repair, it is possible that new therapeutics based on synthetic lethal interactions can be developed to treat these patients with pancreatic ductal adenocarcinoma, as has been accomplished for patients with BRCA gene mutations," the authors write.

Full Text

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs